Comparison of the effect of acetylcysteine and bromhexine on the improvement and prevention of hospitalization in outpatients
One group of patients will be given oral acetylcysteine 600 mg twice daily for 5 days and another group will be given 8 mg bromhexine tablets three times daily for 5 days. Referral, on day 7 and day 14, patients' oxygen levels and hospitalization and death are checked.
Settings and conduct:
This double-blind clinical trial is performed on 92 outpatients referred to Dibaj Municipal Services Center. The diagnosis of Covid-19 is debugged at the health service center and the patient enters the study after the test is confirmed. First, the blood oxygen level of the patients was measured with a pulse oximeter and from 92 patients, they were randomly assigned to group A and the rest to group B, and then to a group of patients taking oral acetylcysteine 600 mg twice daily. For 5 days, the other group is given 8 mg of bromhexine tablets three times a day for 5 days. Then, on day 7 and day 14, the patients are followed up and the patients' blood oxygen saturation level is measured and recorded with a pulse oximeter.
Participants/Inclusion and exclusion criteria:
Inclusion criteria include:
• Adult patients aged 18 to 70 years referred to Dibaj Municipal Service Center
• Outpatients with Covid-19 symptoms after positive Covid-19 RT-PCR test
• Oxygen level 98-92%
• Pregnancy and lactation
.Patients taking nitroglycerin.
This clinical trial is performed on outpatients Covid 19. One group of patients is given oral acetylcysteine 600 mg twice daily for 5 days and another group is given 8 mg bromhexine tablets three times daily for 5 days. On the day of referral, day 7 and day 14, patients' oxygen levels and their hospitalization and death are checked.
Main outcome variables:
Duration of recovery, Duration of hospitalization, Death